Hydroxychloroquine

TLC Reports Second Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 12, 2021
Ophthalmology, NDA, Endo International, ISAM, US, Liposome, SAN, CDSCO, Hydroxychloroquine, TLC, COVID-19, New Drug Application, Safety, Plasma, Hepatotoxicity, GLOBE, Phase, International Society, Congress, Nephrotoxicity, Degenerative disease, Aerosol, FDA, Central Drugs Standard Control Organisation, Pain management, Patient, Amphotericin B, Pharmaceutical industry, Generic drug

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC , a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC , a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
  • Operating revenue for the second quarter of fiscal 2021 was NT$160.2 million (US$5.7 million), a 1,260.2% increase compared to NT$11.8million (US$0.4 million) in the second quarter of fiscal 2020.
  • Operating expenses for the second quarter of fiscal 2021 was NT$251.7million (US$9.0 million), a 6.2% decrease compared to NT$268.4million (US$9.1 million) in the second quarter of fiscal 2020.
  • Net loss for the second quarter of fiscal 2021 was NT$75.5million (US$2.7 million), compared to a loss of NT$242.4million (US$8.2 million) in the second quarter of 2020, or a net loss of NT$0.66 (US$0.02) per share for the second quarter of fiscal 2021, compared to a net loss of NT$3.28 (US$0.11) per share for the second quarter of fiscal 2020.

Lawsuit against Prominent Physician Sends Wrong Message, States the Association of American Physicians and Surgeons (AAPS)

Retrieved on: 
Monday, August 9, 2021
COVID-19 vaccine, Disease, GLOBE, COVID-19, Hydroxychloroquine, FDA, Publication, Budesonide, Health, Paralysis, AAPS, Oath of office, Judgement, Oath, Physician, Vitamin D, National, Patient, Association, Association of American Physicians and Surgeons, Heart failure, Surgeon, NIH, Colchicine, National Institutes of Health, Disclosure, Ivermectin, Omnia, Public relations, Management, Pharmaceutical industry, Health insurance

AAPS has issued the following statement concerning this litigation:

Key Points: 
  • AAPS has issued the following statement concerning this litigation:
    Dr. Peter McCullough ser ved in his prior position for many years with distinction.
  • This is an historical fact, which is on the public record and cited in his hundreds of peer-reviewed publications.
  • Some at his former employer apparently disagree with these well-supported medical opinions, which are the context for its lawsuit.
  • The Association of American Physicians and Surgeons has represented physicians in all specialties since 1943.

InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress

Retrieved on: 
Monday, April 26, 2021
Health sciences, Drugs, Health care, Orphan drugs, Tyrosine kinase inhibitors, Respiratory therapy, Primary alcohols, GS-441524, Bioavailability, Nebulizer, Nintedanib, Hydroxychloroquine

The objective of the Congress is to foster scientific discussions around the current state-of-the-art for aerosols in medicine.\nTLC previously presented an inhalable liposomal nintedanib for enhanced treatment of pulmonary diseases at the 22nd ISAM Congress in Switzerland.

Key Points: 
  • The objective of the Congress is to foster scientific discussions around the current state-of-the-art for aerosols in medicine.\nTLC previously presented an inhalable liposomal nintedanib for enhanced treatment of pulmonary diseases at the 22nd ISAM Congress in Switzerland.
  • However, the low oral bioavailability of GS-441524 means an extremely high oral dose would be required to achieve therapeutic levels.
  • HCQ has shown potential in prophylaxis and/or treatment for COVID-19 in in vitro and preliminary clinical trial studies, but orally administered HCQ cannot reach therapeutic levels due to its dose-limiting toxicities.
  • ISPM19 is designed to be cost-effective, easily accessible and can be self-administered with a portable nebulizer.

China Hydroxychloroquine Markets, 2016-2020 & 2021-2025 - Impact of COVID-19 on the Market

Retrieved on: 
Friday, April 23, 2021
Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Chloroarenes, Quinolines, Hydroxychloroquine, Arthritis, Rheumatoid arthritis, Lupus, Draft:Chloroquine/Hydroxychloroquine and COVID-19, Triple therapy

In 2020, China\'s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.\nHydroxychloroquine is commonly used to prevent and treat malaria.

Key Points: 
  • In 2020, China\'s sales of hydroxychloroquine were CNY 343 million, a slight increase of 0.71% than 2019.\nHydroxychloroquine is commonly used to prevent and treat malaria.
  • Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.
  • In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases.
  • It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.\n2 Sales of Hydroxychloroquine in China, 2016-2020\n2.3 Sales of Hydroxychloroquine by Dosage Form in China, 2016-2020\n3 Analysis of Major Hydroxychloroquine Manufacturers in China, 2016-2020\n3.2 Shanghai Zhongxi Pharmaceutical Co.,Ltd.\n4 Prices of Hydroxychloroquine in China, 2020-2021\n5 Prospect of China\'s Hydroxychloroquine Market, 2021-2025\n'

Hydroxychloroquine Sees a Drop in Demand and Price, Says Beroe Inc

Retrieved on: 
Thursday, April 22, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Demand, Pricing, Health care

The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.

Key Points: 
  • The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.
  • On average, the API prices had increased by 1015 percent, and in some cases, the prices went up by more than 50 percent.
  • The unpredicted rise in the demand of HCQ drove up the prices from June 2020.
  • With no supply-demand crunch, the prices of raw materials are expected to stabilize in the future.\nThe report from Beroe includes:\n"

Hydroxychloroquine Sees a Drop in Demand and Price, Says Beroe Inc

Retrieved on: 
Thursday, April 22, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Demand, Pricing, Health care

The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.

Key Points: 
  • The demand for hydroxychloroquine was at its peak in the second quarter of 2020, when it was being used in the treatment of COVID-19.
  • On average, the API prices had increased by 1015 percent, and in some cases, the prices went up by more than 50 percent.
  • The unpredicted rise in the demand of HCQ drove up the prices from June 2020.
  • With no supply-demand crunch, the prices of raw materials are expected to stabilize in the future.\nThe report from Beroe includes:\n"

China Hydroxychloroquine Market Investigation Report 2021-2025 Featuring Shanghai Zhongxi Pharmaceutical & Sanofi-aventis Ireland - ResearchAndMarkets.com

Retrieved on: 
Monday, April 19, 2021
Manufacturing, Infectious diseases, Health, Pharmaceutical, Chemicals, Plastics, Medical specialties, Medicine, Clinical medicine, Autoimmune diseases, Chloroarenes, Quinolines, Hydroxychloroquine, Sanofi, Rheumatoid arthritis, Lupus, Draft:Chloroquine/Hydroxychloroquine and COVID-19

Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.

Key Points: 
  • Hydroxychloroquine is also used in the treatment of rheumatoid arthritis, lupus erythematosus, and delayed skin lesions purpura.\nThe market demand for hydroxychloroquine in China is relatively large.
  • There are two companies approved for manufacturing hydroxychloroquine, namely Shanghai Zhongxi Pharmaceutical Co., Ltd. and Sanofi-aventis Ireland Ltd. Shanghai Zhongxi Pharmaceutical Co., Ltd. has a larger sales market share with lower prices advantage.
  • In March 2020, the Shanghai Municipal Health Commission in China recommended that hydroxychloroquine be used to treat mild to moderate new coronavirus diseases.
  • It is predicted that its sales will gradually return to the original level, that is, it is mainly used for the treatment of malaria and rheumatoid arthritis.\n2 Sales of Hydroxychloroquine in China, 2016-2020\n2.3 Sales of Hydroxychloroquine by Dosage Form in China, 2016-2020\n3 Analysis of Major Hydroxychloroquine Manufacturers in China, 2016-2020\n3.2 Shanghai Zhongxi Pharmaceutical Co.,Ltd.\n4 Prices of Hydroxychloroquine in China, 2020-2021\n5 Prospect of China\'s Hydroxychloroquine Market, 2021-2025\n'

The Quinism Foundation Encourages Those Injured by Hydroxychloroquine and Related Quinoline Antimalarial Drugs to File Timely Claims for Government Compensation

Retrieved on: 
Friday, March 19, 2021
Chemical compounds, Quinolines, Chloroarenes, Organic compounds, Drugs, Quinism, Mefloquine, Hydroxychloroquine, Chloroquine, Emergency Use Authorization, Encephalopathy, Tafenoquine

[1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).

Key Points: 
  • [1] Hydroxychloroquine and chloroquine were subsequently approved by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA).
  • Dr. Nevin noted that more information on how to file a claim could be found at https://www.hrsa.gov/cicp/filing-benefits , or by visiting the website of The Quinism Foundation, at https://quinism.org .
  • The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on quinism, the medical disorder caused by exposure to quinoline drugs, including tafenoquine, chloroquine, hydroxychloroquine, and mefloquine.
  • Neuropsychiatric Quinism: Chronic Encephalopathy Caused by Poisoning by Mefloquine and Related Quinoline Drugs.

Family Physician Reports Successful Treatment of COVID-19

Retrieved on: 
Tuesday, February 16, 2021
Chloroarenes, Quinolines, Hydroxychloroquine, Chloroquine, Clinical medicine, Health care, Health

Only about half a dozen of approximately 100 patients had to be hospitalized.

Key Points: 
  • Only about half a dozen of approximately 100 patients had to be hospitalized.
  • Dr. Smith learned of the use of hydroxychloroquine (HCQ) in nursing-home patients from a physician in Texas.
  • For more than 38 years he had prescribed HCQ for patients traveling to malarious regions, without difficulty.
  • Local physicians, a cardiologist and an ophthalmologist, told him they had seen no adverse effects from HCQ in their long careers.

Outlook on the Hydroxychloroquine Drugs Global Market to 2030 - Players Include Sanofi, Amneal Pharmaceuticals & Mylan Among Others

Retrieved on: 
Friday, February 12, 2021
Chloroarenes, Quinolines, Medical specialties, Hydroxychloroquine, Chloroquine, Health care, Medicine

Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2030

Key Points: 
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2018-2030
    6.3.
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    7.3.
  • Global Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Region
    8.3.
  • Middle East & Africa Hydroxychloroquine Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
    13.4.